Ernst Ulsperger
Horn, 3580, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Small cell lung cancer: circulating tumor cell lines and expression of mediators of angiogenesis and coagulation.
Journal: Exploration of targeted anti-tumor therapy
Published: October 28, 2022
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia.
Journal: European journal of haematology
Published: March 02, 2021
Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 Patients.
Journal: International journal of molecular sciences
Published: April 05, 2020
Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines.
Journal: Investigational new drugs
Published: June 21, 2019
The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical research.
Journal: Wiener klinische Wochenschrift
Published: April 04, 2019
Expression of Proteolytic Enzymes by Small Cell Lung Cancer Circulating Tumor Cell Lines.
Journal: Cancers
Published: December 28, 2018
Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance.
Journal: Scientific reports
Published: February 23, 2017
A review of the role of surgery for small cell lung cancer and the potential prognostic value of enumeration of circulating tumor cells.
Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: January 12, 2016
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Journal: The Lancet. Oncology
Published: February 22, 2015
Docetaxel in the treatment of non-small cell lung cancer (NSCLC) -- an observational study focusing on symptom improvement.
Journal: Anticancer research
Published: September 12, 2013
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer.
Journal: Investigational new drugs
Published: April 16, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026